EMPD Biomarker Panel for Surgical Margin Assessment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Extramammary Paget disease (EMPD) lacks established treatment guidelines and specific diagnostic markers, making it difficult to diagnose and treat effectively, with existing treatments like imiquimod and ingenol mebutate showing variable response rates and recurrence issues.
Innovation Solution
Measuring the levels of SAM pointed domain containing ETS transcription factor (SPDEF), arginase 2 (ARG2), and adipocyte enhancer-binding protein 1 (ABEP1) in biological samples to diagnose or predict the prognosis of EMPD, and using these biomarkers to screen for agents that can prevent or treat the disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If surgical management is performed with clear margins, then complete tumor removal is achieved, but surgical difficulty increases when margins are unclear
Solution Approach 1:
The patent applies preliminary action by measuring biomarker levels (SPDEF, ARG2, AEBP1) in surgical specimens before final margin assessment is completed. This allows surgeons to identify positive margins early in the resection process and perform additional sampling or extension before closing, thereby achieving complete tumor removal without increasing overall surgical complexity
Solution Approach 2:
The patent replaces the mechanical/visual assessment of surgical margins with a biochemical detection system. Instead of relying solely on pathologist examination of tissue sections, the invention uses immunohistochemical or molecular assays to detect biomarker expression in margin specimens, providing objective data that guides further surgical intervention
2Reliability
If extensive surgery is performed to ensure clear margins, then recurrence risk is reduced, but treatment complexity and morbidity increase
Solution Approach 1:
The patent enables preliminary identification of patients who require extended surgery versus those who can undergo limited resection. By measuring biomarker levels in initial margin specimens, the system predicts recurrence risk before final surgical decisions are made, allowing tailored treatment plans that prevent unnecessary extensive surgery while ensuring adequate resection in high-risk cases
Solution Approach 2:
The patent applies partial action by using biomarker measurement on a selective basis - only on margin specimens from patients with clinically uncertain margins or high-risk features. This avoids the need for universal extensive surgery or universal biomarker testing, optimizing the balance between recurrence prevention and treatment complexity
3Measurement precision
If multiple biomarkers are measured to improve diagnostic accuracy, then diagnosis precision is improved, but measurement complexity increases
Solution Approach 1:
The patent segments the diagnostic process into two stages: (1) initial screening using a panel of biomarkers (SPDEF, ARG2, AEBP1) to identify positive margins, and (2) confirmatory testing or clinical correlation for final diagnosis. This segmentation allows comprehensive biomarker assessment without overwhelming complexity at any single decision point
Solution Approach 2:
The patent merges multiple biomarker assessments into a unified diagnostic algorithm. Rather than evaluating each biomarker separately and making independent decisions, the invention combines the information from SPDEF, ARG2, and AEBP1 measurements into a single integrated margin assessment system that guides surgical management
Data Source
AI summary
The present invention relates to extramammary Paget disease biomarkers, such as SPDEF, ARG2, and ABEP1, and uses thereof that were discovered by exploring the molecular profile as well as performing a comprehensive genetic analysis of EMPD. The present invention investigates how EMPD evolves in the context of treatment and may elucidate a potential mechanism of progression to invasion. Furthermore, the biomarkers of the present invention may be usefully used in the diagnosis or treatment of extramammary Paget disease in that the tissue microenvironments and cell types associated with EMPD may be further characterized using spatial transcriptomics.